Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene

Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.

Read Original Copy